- Home
- ALAR vs ENTX Comparison
ALAR vs ENTX Comparison
Compare ALAR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- ENTX
- Stock Information
- Founded
- ALAR 2013
- ENTX 2010
- Country
- ALAR Israel
- ENTX Israel
- Employees
- ALAR N/A
- ENTX N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALAR Technology
- ENTX Health Care
- Exchange
- ALAR Nasdaq
- ENTX Nasdaq
- Market Cap
- ALAR 94.0M
- ENTX 77.3M
- IPO Year
- ALAR 2018
- ENTX 2018
- Fundamental
- Price
- ALAR $11.24
- ENTX $2.10
- Analyst Decision
- ALAR Strong Buy
- ENTX Strong Buy
- Analyst Count
- ALAR 2
- ENTX 1
- Target Price
- ALAR $24.00
- ENTX $10.00
- AVG Volume (30 Days)
- ALAR 233.2K
- ENTX 54.8K
- Earning Date
- ALAR 11-25-2024
- ENTX 11-08-2024
- Dividend Yield
- ALAR N/A
- ENTX N/A
- EPS Growth
- ALAR N/A
- ENTX N/A
- EPS
- ALAR 0.10
- ENTX N/A
- Revenue
- ALAR $31,561,000.00
- ENTX $99,000.00
- Revenue This Year
- ALAR $22.15
- ENTX N/A
- Revenue Next Year
- ALAR $11.59
- ENTX N/A
- P/E Ratio
- ALAR $10.77
- ENTX N/A
- Revenue Growth
- ALAR 40.80
- ENTX 607.14
- 52 Week Low
- ALAR $4.92
- ENTX $0.52
- 52 Week High
- ALAR $46.69
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- ALAR 40.46
- ENTX 58.28
- Support Level
- ALAR $10.41
- ENTX $2.02
- Resistance Level
- ALAR $12.34
- ENTX $2.45
- Average True Range (ATR)
- ALAR 0.76
- ENTX 0.18
- MACD
- ALAR -0.11
- ENTX 0.01
- Stochastic Oscillator
- ALAR 23.75
- ENTX 59.77
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.